Former MD Anderson President Dr. Charles A. LeMaistre Passes Away at 92
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against the harmful effects of tobacco use and catalyst of the field of cancer prevention, died today in Houston. He was 92. LeMaistre came to MD Anderson as president in 1978 after serving seven years as chancellor of The University of Texas System.
“Mickey was one of the great icons of 20th century...
MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive...
MD Anderson welcomes FDA proposed rule to limit carcinogen levels in smokeless tobacco
The University of Texas MD Anderson Cancer Center fully supports the proposed rule released today by the U.S. Food and Drug Administration...
‘Collateral’ lethality may offer new therapeutic approach for cancers of the pancreas, stomach and colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers.
Scientists at The University of Texas MD Anderson Cancer Center have discovered that during early cancer development when a common tumor suppressor known as SMAD4 is deleted, a nearby...
MD Anderson Submits Letter to the Editor of Wall Street Journal
Dear Editor:
A reduction in force is something no institution wants to do, and it was something we worked tirelessly to avoid at MD...
MD Anderson and Deerfield Management create Vescor LLC to develop novel therapeutics based on inhibiting autophagy for treatment of specific cancers
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by...
MD Anderson and nation’s cancer centers jointly endorse updated HPV vaccine recommendations
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united...
MD Anderson and EMD Serono enter three-year strategic collaboration to accelerate development of investigational oncology/immuno-oncology compounds
The University of Texas MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and...
MD Anderson and Affimed announce clinical immuno-oncology development collaboration
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and...